Evidence map›Paper›PMID 41641032›Full record

ReviewFrontiers in endocrinology2025

Neuropeptidergic systems in psychiatric disorders.

Sadat Hodzic, Therese Riedemann

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sadat HodzicDepartment of Physiological Genomics, Institute of Physiology, Biomedical Center, Ludwig-Maximilians-Universität München, München, Germany.
Therese RiedemannCenter for Physiology, Pathophysiology and Biophysics, Paracelsus Medical University, Salzburg, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuropeptides represent a heterogeneous class of signalling molecules whose release has initially been described in the hypothalamus. Their release often follows a circadian rhythm and basal release may be enhanced by internal and external stressors. Research on the cellular actions of neuropeptides began in the hypothalamus but progressed to the entire brain following observations of neuropeptide and neuropeptide receptor expression throughout the brain. Recent research suggests that the prefrontal cortex (PFC) exhibits particularly high levels of neuropeptides and neuropeptide receptors suggesting that they may modulate cognitive processes necessary for executive function. However, most data on the cellular actions of neuropeptides are derived from non-cortical cells and their relevance to PFC-dependent behaviour is currently not understood. This review aims to bridge the gap between cellular and network actions of neuropeptides and their relevance to behaviour and mood disorders. Therefore, this review summarises the function of the PFC and highlights the effects of selected neuropeptides on cortical processing and PFC-dependent behavioural output. Where available, we compare the actions of neuropeptides in the rodent brain to the human brain and review potential therapeutic benefits of neuropeptides in PFC-dependent neuropsychiatric disorders.

Indexed as

Mental DisordersNeuropeptidesPrefrontal CortexAnimalsBrainHumansNeuropeptidesdepressionneuropeptidesneuropeptide Yorexinoxytocinprefrontal cortexsomatostatinvasoactive intestinal peptide

Identifiers

PMID41641032
PMCPMC12864144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.